CD19 and neoplasm: To assess the in vivo functionality of CD19-CAR T cells with ACAT1 silencing, we used the NSG mouse tumor model, in which the animals were engrafted subcutaneously with 3 × 105 Luciferase+ Raji cells and, after 7 days, mice were infused intravenously with three different groups of CD19-CAR-transduced T cells (5 × 106 cells/mouse) (Figure 5a).